Literature DB >> 12970762

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

B Z Carter1, M Milella, T Tsao, T McQueen, W D Schober, W Hu, N M Dean, L Steelman, J A McCubrey, M Andreeff.   

Abstract

XIAP is a member of the inhibitors-of-apoptosis family of proteins, which inhibit caspases and block cell death, with prognostic importance in AML. Here we demonstrate that cytokines regulate the expression of XIAP in leukemic cell lines and primary AML blasts. Inhibition of phosphatidylinositol-3 kinase (PI3K) with LY294002 and of the mitogen-activated protein kinase (MAPK) cascade by PD98059 resulted in decreased XIAP levels (34+/-8.7 and 23+/-5.7%, respectively). We then generated OCI-AML3 cells with constitutively phosphorylated Akt (p473-Akt) by retroviral gene transfer. Neither these nor Akt inhibitor-treated OCI-AML3 cells showed changes in XIAP levels, suggesting that XIAP expression is regulated by PI3K downstream effectors other than Akt. The induction of XIAP expression by cytokines through PI3K/MAPK pathways is consistent with its role in cell survival. Exposure of leukemic cells to chemotherapeutic agents decreased XIAP protein levels by caspase-dependent XIAP cleavage. Targeting XIAP by XIAP antisense oligonucleotide resulted in downregulation of XIAP, activation of caspases and cell death, and sensitized HL-60 cells to Ara-C. Our results suggest that XIAP is regulated by cytokines through PI3K, and to a lesser degree through MAPK pathways. Selective downregulation of XIAP expression might be of therapeutic benefit to leukemic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970762     DOI: 10.1038/sj.leu.2403113

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  Chemosensitization effects of simultaneous suppression of MDR1 and XIAP in multidrug resistant glioma cells.

Authors:  Zhiqing Zhang; Xiaofang Wang; Suping Wang
Journal:  Med Oncol       Date:  2008-01-23       Impact factor: 3.064

3.  Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.

Authors:  Bing Z Carter; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Deborah A Thomas; Farhad Ravandi; Hagop M Kantarjian; Erich Koller; Michael Andreeff; Steven M Kornblau
Journal:  Blood       Date:  2010-11-01       Impact factor: 22.113

4.  The time course of Akt and ERK activation on XIAP expression in HEK 293 cell line.

Authors:  Mousa Abkhezr; Ali Reza Keramati; Seyed Nasser Ostad; Jamshid Davoodi; Mohammad H Ghahremani
Journal:  Mol Biol Rep       Date:  2009-08-02       Impact factor: 2.316

5.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

Review 6.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

7.  Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.

Authors:  Ji Hye Yim; Won Gu Kim; Min Ji Jeon; Ji Min Han; Tae Yong Kim; Jong Ho Yoon; Suck Joon Hong; Dong Eun Song; Gyungyub Gong; Young Kee Shong; Won Bae Kim
Journal:  Thyroid       Date:  2013-12-13       Impact factor: 6.568

8.  Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

Authors:  John F DiPersio; Harry P Erba; Richard A Larson; Selina M Luger; Martin S Tallman; Jeffrey M Brill; Gregoire Vuagniaux; Elisabeth Rouits; J Mel Sorensen; Claudio Zanna
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

9.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

10.  Manipulation of neutrophil-like HL-60 cells for the study of directed cell migration.

Authors:  Arthur Millius; Orion D Weiner
Journal:  Methods Mol Biol       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.